initial public offerings (IPOs) trading on American exchanges

Friday, January 29, 2021

Atea Pharmaceuticals (AVIR) began trading on the Nasdaq on Fri 30 Oct 20

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. 
  • Sector(s): Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 39
  • Incorporated in 2012 
  • Headquartered in Boston, Massachusetts
Atea Pharmaceuticals upsized offering by 1.5 mln shares and prices 12.5 mln share IPO at $24.00 per share, at the high end of the $22-24 expected range

No comments:

Post a Comment